{"id":1345,"date":"2024-06-06T11:55:40","date_gmt":"2024-06-06T11:55:40","guid":{"rendered":"https:\/\/novaptech.com\/?page_id=1345"},"modified":"2025-02-11T14:15:54","modified_gmt":"2025-02-11T14:15:54","slug":"aptamers-as-therapeutics","status":"publish","type":"page","link":"https:\/\/novaptech.com\/fr\/portfolio_page\/aptamers-as-therapeutics\/","title":{"rendered":"Les aptam\u00e8res comme agents th\u00e9rapeutiques"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Les aptam\u00e8res comme agents th\u00e9rapeutiques<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Les aptam\u00e8res poss\u00e8dent un immense potentiel en tant qu'agents th\u00e9rapeutiques. Ils peuvent cibler des mol\u00e9cules intracellulaires, des composants membranaires ou des mol\u00e9cules circulantes. Ils peuvent \u00eatre utilis\u00e9s comme vecteurs de d\u00e9livrance de m\u00e9dicaments vers des cellules d\u2019int\u00e9r\u00eat. Ils peuvent agir comme antagonistes (en emp\u00eachant une interaction sp\u00e9cifique r\u00e9cepteur-ligand) ou comme agonistes (en se liant \u00e0 un r\u00e9cepteur et en activant un signal). Les aptam\u00e8res peuvent \u00eatre facilement modifi\u00e9s afin d\u2019am\u00e9liorer leurs propri\u00e9t\u00e9s, notamment en les rendant plus r\u00e9sistants aux nucl\u00e9ases ou en augmentant leur demi-vie in vivo. Ils induisent une r\u00e9ponse immunitaire minimale in vivo. Plusieurs essais cliniques sont en cours.<\/p>

Novaptech contribue dans ce domaine ; voir par exemple :\u00a0<\/span><\/p>

Millozzi, F., Mil\u00e1n-Rois, P., Sett, A., Delli Carpini, G., De Bardi, M., Gisbert-Garzar\u00e1n, M., Sandon\u00e0, M., Rodr\u00edguez-D\u00edaz, C., Mart\u00ednez-Mingo, M., Pardo, I., Esposito, F., Viscomi, M. T., Bouch\u00e9, M., Parolini, O., Saccone, V., Toulm\u00e9, J.-J., Somoza, \u00c1., & Palacios, D. (2025). Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles.<\/strong> <\/a>Nature Communications<\/em>, 16<\/strong>, Article 577.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Aptamers as therapeutics Aptamers have a huge potential as therapeutic agents. They can be addressed to intracellular targets, to membrane components or to circulating molecules. They can be used as drug-delivery agents to cells of interest. They can be employed as antagonists (preventing a specific receptor-ligand interaction), or as agonists (binding to a receptor and activating a signal). Aptamers can be easily modified for improving their properties (making them more resistant to nucleases or increasing their in vivo half-life). They induce a minimal immune response in vivo. Several clinical trials are on-going. Novaptech contributes to this field; see for instance :\u00a0 Millozzi, F., Mil\u00e1n-Rois, P., Sett, A., Delli Carpini, G., De Bardi, M., Gisbert-Garzar\u00e1n, M., Sandon\u00e0, M., Rodr\u00edguez-D\u00edaz, C., Mart\u00ednez-Mingo, M., Pardo, I., Esposito, F., Viscomi, M. T., Bouch\u00e9, M., Parolini, O., Saccone, V., Toulm\u00e9, J.-J., Somoza, \u00c1., & Palacios, D. (2025). Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles. Nature Communications, 16, Article 577.<\/p>","protected":false},"author":1,"featured_media":0,"parent":1339,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-1345","page","type-page","status-publish","hentry"],"yoast_head":"\nAptamers as therapeutics - Novaptech<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaptech.com\/fr\/portfolio_page\/aptamers-as-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptamers as therapeutics - Novaptech\" \/>\n<meta property=\"og:description\" content=\"Aptamers as therapeutics Aptamers have a huge potential as therapeutic agents. They can be addressed to intracellular targets, to membrane components or to circulating molecules. They can be used as drug-delivery agents to cells of interest. They can be employed as antagonists (preventing a specific receptor-ligand interaction), or as agonists (binding to a receptor and activating a signal). Aptamers can be easily modified for improving their properties (making them more resistant to nucleases or increasing their in vivo half-life). They induce a minimal immune response in vivo. Several clinical trials are on-going. Novaptech contributes to this field; see for instance :\u00a0 Millozzi, F., Mil\u00e1n-Rois, P., Sett, A., Delli Carpini, G., De Bardi, M., Gisbert-Garzar\u00e1n, M., Sandon\u00e0, M., Rodr\u00edguez-D\u00edaz, C., Mart\u00ednez-Mingo, M., Pardo, I., Esposito, F., Viscomi, M. T., Bouch\u00e9, M., Parolini, O., Saccone, V., Toulm\u00e9, J.-J., Somoza, \u00c1., & Palacios, D. (2025). Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles. Nature Communications, 16, Article 577.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaptech.com\/fr\/portfolio_page\/aptamers-as-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Novaptech\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-11T14:15:54+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/\",\"url\":\"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/\",\"name\":\"Aptamers as therapeutics - Novaptech\",\"isPartOf\":{\"@id\":\"https:\/\/novaptech.com\/en\/#website\"},\"datePublished\":\"2024-06-06T11:55:40+00:00\",\"dateModified\":\"2025-02-11T14:15:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/novaptech.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Portfolio page\",\"item\":\"https:\/\/novaptech.com\/portfolio_page\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Aptamers as therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/novaptech.com\/en\/#website\",\"url\":\"https:\/\/novaptech.com\/en\/\",\"name\":\"Novaptech\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/novaptech.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/novaptech.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/novaptech.com\/en\/#organization\",\"name\":\"Novaptech\",\"url\":\"https:\/\/novaptech.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/novaptech.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/novaptech.com\/wp-content\/uploads\/2024\/06\/cropped-LOGO.png\",\"contentUrl\":\"https:\/\/novaptech.com\/wp-content\/uploads\/2024\/06\/cropped-LOGO.png\",\"width\":335,\"height\":140,\"caption\":\"Novaptech\"},\"image\":{\"@id\":\"https:\/\/novaptech.com\/en\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptamers as therapeutics - Novaptech","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaptech.com\/fr\/portfolio_page\/aptamers-as-therapeutics\/","og_locale":"fr_FR","og_type":"article","og_title":"Aptamers as therapeutics - Novaptech","og_description":"Aptamers as therapeutics Aptamers have a huge potential as therapeutic agents. They can be addressed to intracellular targets, to membrane components or to circulating molecules. They can be used as drug-delivery agents to cells of interest. They can be employed as antagonists (preventing a specific receptor-ligand interaction), or as agonists (binding to a receptor and activating a signal). Aptamers can be easily modified for improving their properties (making them more resistant to nucleases or increasing their in vivo half-life). They induce a minimal immune response in vivo. Several clinical trials are on-going. Novaptech contributes to this field; see for instance :\u00a0 Millozzi, F., Mil\u00e1n-Rois, P., Sett, A., Delli Carpini, G., De Bardi, M., Gisbert-Garzar\u00e1n, M., Sandon\u00e0, M., Rodr\u00edguez-D\u00edaz, C., Mart\u00ednez-Mingo, M., Pardo, I., Esposito, F., Viscomi, M. T., Bouch\u00e9, M., Parolini, O., Saccone, V., Toulm\u00e9, J.-J., Somoza, \u00c1., & Palacios, D. (2025). Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles. Nature Communications, 16, Article 577.","og_url":"https:\/\/novaptech.com\/fr\/portfolio_page\/aptamers-as-therapeutics\/","og_site_name":"Novaptech","article_modified_time":"2025-02-11T14:15:54+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/","url":"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/","name":"Aptamers as therapeutics - Novaptech","isPartOf":{"@id":"https:\/\/novaptech.com\/en\/#website"},"datePublished":"2024-06-06T11:55:40+00:00","dateModified":"2025-02-11T14:15:54+00:00","breadcrumb":{"@id":"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/novaptech.com\/en\/"},{"@type":"ListItem","position":2,"name":"Portfolio page","item":"https:\/\/novaptech.com\/portfolio_page\/"},{"@type":"ListItem","position":3,"name":"Aptamers as therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/novaptech.com\/en\/#website","url":"https:\/\/novaptech.com\/en\/","name":"Novaptech","description":"","publisher":{"@id":"https:\/\/novaptech.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/novaptech.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/novaptech.com\/en\/#organization","name":"Novaptech","url":"https:\/\/novaptech.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/novaptech.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/novaptech.com\/wp-content\/uploads\/2024\/06\/cropped-LOGO.png","contentUrl":"https:\/\/novaptech.com\/wp-content\/uploads\/2024\/06\/cropped-LOGO.png","width":335,"height":140,"caption":"Novaptech"},"image":{"@id":"https:\/\/novaptech.com\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/novaptech.com\/fr\/wp-json\/wp\/v2\/pages\/1345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/novaptech.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/novaptech.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/novaptech.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/novaptech.com\/fr\/wp-json\/wp\/v2\/comments?post=1345"}],"version-history":[{"count":16,"href":"https:\/\/novaptech.com\/fr\/wp-json\/wp\/v2\/pages\/1345\/revisions"}],"predecessor-version":[{"id":3431,"href":"https:\/\/novaptech.com\/fr\/wp-json\/wp\/v2\/pages\/1345\/revisions\/3431"}],"up":[{"embeddable":true,"href":"https:\/\/novaptech.com\/fr\/wp-json\/wp\/v2\/pages\/1339"}],"wp:attachment":[{"href":"https:\/\/novaptech.com\/fr\/wp-json\/wp\/v2\/media?parent=1345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}